Compliance

Lawmakers eye pricing

The Senate Judiciary Committee's antitrust panel is looking into how three major pharmaceutical manufacturers decided to set minimum prices for their contact lenses.

Pitting Big Data against nonadherence

Pitting Big Data against nonadherence

By

A young company is hoping its analytics platform can help doctors and pharma figure out who's going to stop taking their medication, and get them back on track.

OPDP not happy with Diclegis promo

OPDP not happy with Diclegis promo

By

The bad-ad watchdog issued an untitled letter to drugmaker Duchesnay in November.

Novartis under scrutiny in Japan

Novartis under scrutiny in Japan

By

The scandal over Diovan draws regulatory attention.

CME compliance trends up among some outfits

By

Some providers of CME are getting better at complying with accreditation criteria, data show, yet many are still struggling to meet a stricter set of requirements.

Merz web-copy shortcuts don't sit well with OPDP

By

FDA's Office of Prescription Drug Promotion issued an Untitled Letter over what it says are misleading copy and overstated efficacy claims online.

OPDP sends Warning Letter to Acorda

By

The ad watchdog flagged the drug maker for what it said was yet another misleading Ampyra promotional piece.

Researchers spot $213B of wasteful drug spending

Researchers spot $213B of wasteful drug spending

By

For a country bent on healthcare cost control, findings represent an opportunity: authors say nearly 8% of the nation's total outlay could have been avoided.

GSK's Connelly: We've changed our ways (and please don't imprison execs)

GSK's Connelly: We've changed our ways (and please don't imprison execs)

By

GlaxoSmithKline's Dierdre Connelly peeled back the curtain on the company's sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.

Pharma execs: MLR teams are friendlier on digital

By

Pharma's med/legal/regulatory (MLR) teams, managers of risk and so often the scapegoats for creating roadblocks to digital innovation, were discussed in a much friendlier light by digital marketers at last week's ExL Digital Pharma East conference in Philadelphia.

GSK seeks to span digital divide with social/digital dragnet

By

GlaxoSmithKline is souping up its social media monitoring with a digital strategy it says will create processes that are standard enough to streamline communications, but flexible enough to meet local requirements.

GSK hopes $3-bil. off-label settlement will end legal woes

By

GlaxoSmithKline's deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.

Omnicom, CAHG sign up for regulatory compliance training

By

Agency CAHG became the first healthcare marketing shop to undergo training and certification in regulatory compliance through the Center for Communication Compliance, and its parent company, Omnicom, said all of its healthcare agencies will follow suit.

Merck web widget points to future adherence fix

Merck web widget points to future adherence fix

By

Asking consumers to gauge their risk for non-adherence, Merck is deploying a one-minute survey dubbed the Adherence Estimator that may be the way forward for keeping patients on-treatment.

Majority of pharma journal ads not FDA-compliant: study

By

Four out of five ads analyzed in a study of physician-directed pharmaceutical advertising would definitely not pass FDA muster, or might have trouble doing so, said researchers. Their findings may have implications for the FDA, DDMAC and the "Bad Ad" program.

Feds subpoena Merck on marketing of hepatitis, cancer drugs

By

Merck said it received a subpoena related to marketing and selling activities with respect to three drugs: Temodar, PegIntron and Intron A.

Pain drug monitoring firm enticed docs to use test, qui-tam suit charges

By

A national lab promised doctors they could enrich themselves by as much as $2 million a year through a scheme that involved billing payers multiple times for the same urinary drug test, a whistleblower suit alleges.

Mobile pill cap takes social approach to raising compliance

Mobile pill cap takes social approach to raising compliance

By

A company that markets a pill cap with a built-in cellular connection puts a social twist on getting patients to take their meds.

FDA steps up enforcement of generics firm

By

The FDA issued a warning to Canadian generic drug maker Apotex last month, marking the firm's second citation in less than a year.

Scripts going unfilled at 'unprecedented' rate

By

Patients not taking or refilling medications on time costs the pharmaceutical industry billions each year. The housing bubble and recession have helped write a new chapter in the compliance story, as higher numbers of new prescriptions simply go unfilled because patients either cannot afford, or are unwilling, to pay for them.

Everyday Health's virtual doc dispenses compliance advice

Everyday Health's virtual doc dispenses compliance advice

By

Everyday Health is launching a condition-based "virtual doctor" feature for patients with chronic conditions that emphasizes compliance.

Pharmacy adherence pilot boosted refills 36%

By

Pharmacies that counseled patients for a chronic COPD/respiratory drug saw an average increase in refill rates of more than 36% through the fifth fill, said McKesson.

Predicting Product Launch Success: An Ace in the Whole

Can pharma companies really predict the success of new product launches? Patrick Howie and Mike Luby report on how pharmas can hone in on physicians' actual prescribing behavior versus stated intentions

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.